Fusion Capital LLC Buys 2,110 Shares of Sanofi (NASDAQ:SNY)

Fusion Capital LLC increased its stake in Sanofi (NASDAQ:SNY) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 134,687 shares of the company’s stock after acquiring an additional 2,110 shares during the period. Sanofi comprises about 2.6% of Fusion Capital LLC’s holdings, making the stock its 15th largest holding. Fusion Capital LLC’s holdings in Sanofi were worth $6,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new position in shares of Sanofi in the third quarter valued at about $7,038,000. Allworth Financial LP increased its holdings in Sanofi by 7.5% during the 3rd quarter. Allworth Financial LP now owns 5,081 shares of the company’s stock valued at $293,000 after purchasing an additional 355 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Sanofi by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,721 shares of the company’s stock valued at $676,000 after purchasing an additional 2,100 shares during the last quarter. Arkadios Wealth Advisors purchased a new stake in Sanofi in the 3rd quarter worth approximately $228,000. Finally, First Trust Direct Indexing L.P. grew its position in shares of Sanofi by 3.1% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 26,359 shares of the company’s stock worth $1,519,000 after buying an additional 791 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY stock opened at $54.14 on Friday. The business’s fifty day moving average is $51.51 and its 200 day moving average is $52.59. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market cap of $137.40 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent analyst reports. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.